{"id":"NCT04492020","sponsor":"AbbVie","briefTitle":"Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-21","primaryCompletion":"2022-04-19","completion":"2022-04-19","firstPosted":"2020-07-30","resultsPosted":"2023-05-31","lastUpdate":"2023-05-31"},"enrollment":518,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Ubrogepant 100 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Treatment Sequence A","type":"EXPERIMENTAL"},{"label":"Treatment Sequence B","type":"EXPERIMENTAL"}],"summary":"Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome","primaryOutcome":{"measure":"Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose","timeFrame":"24 hours after taking double-blind study intervention during the prodrome","effectByArm":[{"arm":"Placebo","deltaMin":121,"sd":null},{"arm":"Ubrogepant 100 mg","deltaMin":190,"sd":null}],"pValues":[{"comp":"OG001","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":73,"countries":["United States"]},"refs":{"pmids":["39982105","39399572","39197113","37979595"],"seeAlso":["https://www.allerganclinicaltrials.com/,http://www.investigatordatabank.org/"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":462},"commonTop":["NAUSEA","DIZZINESS","FATIGUE","SOMNOLENCE"]}}